/Companies

Sprint Bioscience

Huddinge, SE · 1 known investors

Find your way into Sprint Bioscience

Each arrow is one introduction. Sign up to fill in the first one.

164 people can intro you to Martin

Ask Peter Werme to introduce you to Martin Andersson

You →Peter · together at Sprint Bioscience →Martin

Sign up to find every way you can get introduced to Sprint Bioscience

  • Your email: who you already know at Sprint Bioscience, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Sprint Bioscience team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sprint Bioscience is a pharmaceutical company developing oncology drug candidates aimed at new treatments for hard-to-treat cancers. It uses a fragment-based drug discovery approach and out-licenses its drug programs to global pharmaceutical companies during the preclinical phase.

Founders & leadership

MAMartin Andersson
Martin AnderssonCo-founder and CSOMartin Andersson has a background in molecular biology, protein science, structural biology, cancer biology, and immuno-oncology, along with operational and strategic leadership experience in oncology drug discovery. He is a founder of Sprint Bioscience, a Swedish pharmaceutical company developing oncology drug candidates.

Investors · 1

Frequently asked questions

What does Sprint Bioscience do?
Sprint Bioscience is a pharmaceutical company developing oncology drug candidates aimed at new treatments for hard-to-treat cancers. It uses a fragment-based drug discovery approach and out-licenses its drug programs to global pharmaceutical companies during the preclinical phase.
Who founded Sprint Bioscience?
Sprint Bioscience was founded by Martin Andersson.
Who are Sprint Bioscience's investors?
Sprint Bioscience's investors include First Venture.
Where is Sprint Bioscience headquartered?
Sprint Bioscience is headquartered in Huddinge, SE.